Transgene Biotek
- Market cap
- ₹ 17 Cr.
- P/E
- 2.3x
- P/B
- 2.14x
- 52-week range
- 1.83 – 4.27
- ROE
- −18%
- ROCE
- −2.4%
- Dividend yield
- 0%
- Debt / equity
- 2.05
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Transgene Biotek Limited is an India-based biotechnology company. It is engaged in the research and development of vaccines, oncology, and new drug delivery technologies. Its portfolio of products includes oncology, autoimmunity, drug delivery and biogenetics. The Company offers TrabiAAV, which is a platform for the delivery of micro-ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy and CRISPR/cas 9 technologies. Its monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL drug is focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-1203 drug is used to strengthen cell-mediated immunity and complete the elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus drug suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Transgene Biotek against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)2.3 against a typical 21: cheaper than most peers (1st = cheapest).2nd of 34
- Sales growth+20% against a typical +19.1% from a year earlier.14th of 31
- Share price, 3 months−25.8% against a typical −7.7%.31st of 33
- Size₹ 16.8 Cr. market value against a typical ₹ 83 Cr. (1st = largest).27th of 34
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit | −0 | −0 | −0 | −0 | −0 | −0 | −1 | −0 | −0 | −0 | −0 | −0 |
| OPM % | −240% | −220% | −540% | −820% | −116.7% | −112.5% | −675% | −260% | −160% | −100% | −560% | −100% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | −0 | 0 | −0 | −0 | −1 | −0 | −0 | −0 | −0 | −0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | −0 | −0 | −0 | 0 | −0 | −0 | −1 | −0 | −0 | −0 | −0 | −0 |
| EPS in Rs | −0.02 | −0.02 | −0.04 | 0.03 | −0.01 | −0.01 | −0.09 | −0.06 | −0.05 | −0.05 | −0.06 | −0.05 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 2%
- 5 Years
- 4%
- 3 Years
- 52%
- TTM
- −22%
- 10 Years
- 7%
- 5 Years
- 13%
- 3 Years
- 20%
- TTM
- −24%
- 10 Years
- 3%
- 5 Years
- −5%
- 3 Years
- −11%
- TTM
- —
- 10 Years
- −23%
- 5 Years
- −30%
- 3 Years
- −10%
- TTM
- —
Peers
Listed companies in the same business.
| Transgene Biotek | ₹ 2.24 | ₹ 17 Cr. | 2.3x | 2.1x | −18% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- K. Koteswara Rao
- Managing Director
Prices are delayed and for information only. Nothing on this page is investment advice.